Xu Jingren

Xu Jingren (Chinese: 徐镜人; born 1944) is the chairman and president of Yangtze River Pharmaceutical Group,[2] National People's Congress delegate and honorary vice-minister in China's Ministry of Health. Xu has been an outspoken research leader in China, where he has frequently called for labor reform and business regulation.[3] As of 2018, his estimated net worth is USD$4.6 billion,[4] one of four family members to be listed among the world's wealthiest.

Xu Jingren
徐镜人
Born1944 (age 7677)
EducationB.A.
OccupationPharmaceutical executive, philanthropist
Net worthUSD$4.6 billion (October 2018)[1]
Children2

Family

The family were noted victims of the 2015 Chinese stock market crash, during which they lost approximately 40% of their previously estimated USD$8 billion combined net worth.[5] Despite this, Xu Jingren and his relatives continue to be mentioned as one of China's top "vampire billionaire" families with majority investments abroad.[6][7][8] Notable international initiatives include the 2017 YRPG subsidiary[9] merger and rebranding of global drug manufacturer ShangPharma[10] by group CEO Michael Hui and board vice-chair Aaron Shang, with a stated intent of expanding North American operations leading to development of San Francisco-based venture portfolio ShangPharma Innovation.[11][12][13]

References

  1. "Xu Jingren". Forbes.com. Retrieved 5 October 2018.
  2. "Company Overview of Jiangsu Yangtze River Pharmaceutical Group Company Ltd". Bloomberg.com/. Bloomberg Business.
  3. "Deputy: cost cutting affects public health". Npc.gov.cn. NPC.
  4. "Xu Jingren Net Worth". Forbes.com. Forbes Magazine.
  5. "China's Richest Billionaires Lost $195 Billion In One Month Amid Stock Market Rout". Forbes.com. Forbes Investing. Retrieved 22 October 2015.
  6. Lu Stout, Kristie. "Meet China's 1%: The billionaires in Beijing's halls of power". edition.cnn.com/. CNN. Retrieved 22 October 2015.
  7. Hoogewerf, Richard. "Who are China's 'vampire' billionaires?". money.cnn.com/. CNN. Retrieved 22 October 2015.
  8. Branigan, Tania. "Politburo, army, casinos: China's corruption crackdown spreads". Theguardian.com. The Guardian UK. Retrieved 22 October 2015.
  9. "Yangtze River Pharmaceutical(Group) Co". CPhI SEA | Bangkok is Calling. 2019-01-11. Retrieved 2019-12-19.
  10. Corporation, ShangPharma. "ShangPharma Corporation Announces Completion of Merger". www.prnewswire.com. Retrieved 2019-12-19.
  11. "ShangPharma Announces Second Milestone in Move to Enter Chinese Capital Market". ChemPartner.com. 2017.
  12. "How this Chinese biotech player is building and boosting a network of startups". www.bizjournals.com. Retrieved 2019-12-19.
  13. "ShangPharma Innovation Incubator Expansion Is Taking Strong Root in the Bay Area". BioSpace. Retrieved 2019-12-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.